Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570711 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Acerta Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02570711 is a Phase 2 study that was terminated before completion, run by Acerta Pharma. The registered enrollment target is 3 participants.
The verdict
NCT02570711, a Phase 2 study, was terminated before completion, sponsored by Acerta Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with previously untreated metastatic pancreatic cancer using standard response criteria
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG ACP-196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-10-13 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02570711
The ClinicalTrials.gov registry entry for NCT02570711 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02570711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02570711 about?
NCT02570711 is a clinical study titled "Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer". To evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with previously untreated metastatic pancreatic cancer using standard response criteria
What is the current status of trial NCT02570711?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2015-10-13. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02570711?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), ACP-196 (DRUG).
Who is sponsoring clinical trial NCT02570711?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.